Table 3.
Collection years (n) | Compound | Range | MIC50 | MIC90 | CLSI Interpretationb |
||
---|---|---|---|---|---|---|---|
(µg/mL) | %S | %I | %R | ||||
2015‒2017 (2054) | Amikacin | ≤ 0.25 – > 32 | 4 | > 32 | 82.0 | 3.4 | 14.6 |
Aztreonam | 0.06 – > 128 | 8 | 64 | 58.9 | 13.9 | 27.2 | |
Cefepime | 0.5 – > 16 | 4 | > 16 | 72.5 | 10.7 | 16.8 | |
Ceftazidime | 0.06 – > 128 | 4 | 128 | 69.2 | 4.7 | 26.1 | |
Ceftazidime-avibactam | 0.03 – > 128 | 2 | 32 | 86.6 | NA | 13.4 | |
Colistin | ≤ 0.06 – > 8 | 1 | 2 | NA | 99.3 | 0.7 | |
Imipenem | 0.12 – > 8 | 2 | > 8 | 59.9 | 5.8 | 34.2 | |
Levofloxacin | 0.015 – > 8 | 1 | > 8 | 59.0 | 7.5 | 33.5 | |
Meropenem | ≤ 0.004 – > 8 | 1 | > 8 | 65.0 | 5.7 | 29.3 | |
Piperacillin Tazobactam | ≤ 0.25 – > 128 | 8 | > 128 | 66.2 | 14.4 | 19.4 | |
2018‒2020 (2560) | Amikacin | ≤ 0.25 – > 64 | 4 | 64 | 81.1 | 3.1 | 15.8 |
Aztreonam | 0.12 – > 128 | 8 | 64 | 62.3 | 14.1 | 23.6 | |
Cefepime | ≤ 0.12 – > 32 | 4 | > 32 | 71.3 | 10.7 | 17.9 | |
Ceftazidime | 0.25 – > 128 | 4 | 64 | 70.9 | 4.4 | 24.6 | |
Ceftazidime-avibactam | ≤ 0.03 – > 128 | 2 | 32 | 85.3 | NA | 14.7 | |
Colistin | ≤ 0.12 – > 8 | 1 | 2 | NA | 99.8 | 0.2 | |
Imipenem | 0.12 – > 8 | 2 | >8 | 56.7 | 8.9 | 34.4 | |
Levofloxacin | ≤ 0.25 – > 8 | 0.5 | >8 | 62.2 | 8.1 | 29.7 | |
Meropenem | ≤ 0.06 – > 16 | 1 | >16 | 65.0 | 6.4 | 28.6 | |
Piperacillin Tazobactam | ≤ 0.12 – > 64 | 8 | >64 | 67.5 | 14.3 | 18.3 |
Countries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
S, susceptible; I, intermediate; R, resistant.